Xbrane Biopharma AB
STO:XBRANE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.715
36.775
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Wall Street
Price Targets
XBRANE Price Targets Summary
Xbrane Biopharma AB
According to Wall Street analysts, the average 1-year price target for
XBRANE
is 63.75 SEK
with a low forecast of 63.125 SEK and a high forecast of 65.625 SEK.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is XBRANE's stock price target?
Price Target
63.75
SEK
According to Wall Street analysts, the average 1-year price target for
XBRANE
is 63.75 SEK
with a low forecast of 63.125 SEK and a high forecast of 65.625 SEK.
What is Xbrane Biopharma AB's Revenue forecast?
Projected CAGR
38%
For the last 11 years the
compound annual growth rate for
Xbrane Biopharma AB's revenue is
88%.
The projected
CAGR
for the next 3 years is
38%.
